Freeport-McMoRan: Grasberg Remains On Schedule, And I Remain At Buy

Freeport-McMoRan remains rated Buy, with Grasberg recovery on schedule and robust cash flows from U.S. and South American mines supporting the outlook. The shares trade at 6.2x modeled 2027 EBITDA, below historical levels, despite reduced copper sales and higher capex. Q3 cost and cash-flow headwinds from delayed Indonesian gold sales are expected to reverse in Q4, alongside lower unit costs.

Analysis

The setup is an execution-and-timing trade, not yet proof of a durable earnings inflection. If delayed gold sales shift into Q4 as expected, reported cash flow and unit costs can improve without any underlying change in copper demand or mine productivity; the market may over-credit that rebound unless shipment, production and cost data confirm it. The more consequential value driver is Grasberg’s recovery: delivery delays or weaker-than-modeled output would hit both expected sales and confidence in the 2027 EBITDA denominator supporting the low-multiple argument.

Over the next 1–3 months, monitor Q4 gold-sale realization, copper production, unit costs and capex against company guidance. A clean recovery could narrow FCX’s discount to diversified peers such as BHP and Rio Tinto, but that relative valuation case is conditional: the stated 6.2x is based on modeled 2027 EBITDA, so it is not a standalone margin of safety. Over 6–18 months, copper demand and supply discipline matter more than the timing of one quarter’s gold sales; a weaker copper price could overwhelm operational progress.

Contrarian risk: the temporary-headwind framing may be right, but investors could be treating expected normalization as already earned while overlooking capex and reduced copper sales. No need to chase on this information alone; favor confirmation over headline valuation. Thesis is weakened by missed Grasberg milestones, continued cost inflation, capex above plan, or Q4 sales failing to normalize.

Key Decisions for Investors

• Hold or build FCX exposure only on confirmation of Grasberg recovery and Q4 cost/cash-flow normalization; stage entries rather than treating the modeled 2027 EBITDA multiple as a catalyst by itself.
• Use the next operating update as the near-term trigger: verify gold sales actually shift into Q4 and compare copper output, unit costs and capex with guidance. If these miss, reduce exposure rather than assuming the shortfall is merely timing.
• For relative-value books, consider FCX against diversified miners such as BHP or Rio Tinto only if Grasberg execution improves while copper-price exposure remains acceptable; the thesis is operational convergence, not a claim that FCX is categorically cheaper on comparable verified earnings.
• Falsification watch: a material Grasberg schedule setback, persistent unit-cost pressure, capex materially above plan, or a weaker copper-price outlook. Reassess the valuation case if modeled 2027 EBITDA falls, since the cited multiple can rise even with an unchanged share price.